INGESTEM provide evolving services and cutting-edge technologies based on pluripotent stem cells to develop advanced therapies in frequent and rare diseases with unmet medical needs.

We are focus on customers’needs in reprogramming, culturing, characterizing and differentiating stem cells to create disease-specific cell-based assays and models for high and/or medium throughput drug screening programs and toxicity studies, and to design advanced cellular/gene therapy products in the field of immuno-oncology and regenerative medicine.

We adopt a customer-centered approach by providing innovative solutions, cost-effective products, resources and technologies suitable for any research and industrial needs.

ESTeam Paris-Sud (Inserm, Université Paris Saclay, Genopole Evry)

  • Generation of human IPSC lines via reprogramming from various starting cells-research grade (expert in malignancy – solid tumor and hematology) and characterizations (international standards: pluripotency assays, cell identity viability, sanitary tests)
  • Generation of bioengineering of organoïds by 3D-culture methods from iPSC and progenitors (somatic and hereditary cancer models)
  • Genome editing of IPSC lines and derived (Cells and organoids)
  • Advanced Manufacturing of IPSC Master Banks and derived cells with development of suitability standards for analytic tests (expansion in close system culture automation, cGMP batch > 109)
  • Evaluation of iPSC-derived cell therapy products (genomic integrity assays, immunogenicity, tumorigenicity, potency assays evaluating functionality, mode of action)
  • Access cGMP-compliant production facility and close system automation

I-Stem (Évry)

  • Large scale and automated production of human pluripotent cells (hESC/hiPSC research grade) from healthy and/or mutation-bearing subjects (expert in rare diseases)
  • Large scale and automated production of large banks of progeny derived from human pluripotent cells (hES/hiPS research grade) from healthy and/or mutation-bearing subjects (RPE, MSC, Keratinocytes, NSC)
  • High and/or medium throughput screening of molecules with therapeutic potential

IGBMC (Strasbourg)

  • Cell-based assay development for high throughput screening
  • siRNA-based and small molecule screening (cell-based assays)
  • CRISPR-Cas9 pooled lentiviral screening (knockout, activation, repression) on Cas9 cell lines
  • CRISPR/Cas9 genome-wide screening method

PrimaStem/SBRI (Lyon)

  • Production of cynomolgus macaque (Macaca fascicularis) embryos by in vitro fertilization
  • Production of macaque monkey (Macaca mulatta or Macaca fascicularis) iPSC lines
  • Monkey macaque cynomolgus (Macaca fascicularis) + autologous iPSC line
  • Production of transgenic macaques using lentiviral vectors

SAFE-iPS (Montpellier)

  • Production and characterization of human iPSC lines (expertise: aging diseases)
  • Characterization of IPSC lines: International standards: pluripotency assays, geno-identity, viability, sanitary tests
  • Set up differentiation Protocols
  • Production and characterization of organoïds (pancreatic islets; other)
  • Equipment rental dedicated to cell culture such as the Ruskin hood